Li Lan, MD, PhD
Associate Professor of Radiation Oncology
Massachusetts General Hospital Cancer Center
Harvard Medical School
Center for Cancer Research
Explore the Lan Lab
Elevated oxidative stress and DNA replication stress are common in cancers. On one hand, these intrinsic stresses in cancer cells promote tumor initiation and progression. On the other hand, these stresses render cancer cells sensitive to radiation and chemotherapies. The Lan laboratory is especially interested in understanding how cancer cells respond to oxidative and replication stresses through DNA repair pathways and developing new strategies to target these pathways in cancer therapy. The Lan lab developed the first molecular assay to study the oxidative damage response at specific chromosomal loci. Recently, we discovered and delineated a novel DNA repair pathway—mRNA-mediated repair—that protects the transcribed regions of the genome. We also study mechanisms of telomere protection, a cancer survival mechanism, in cancer therapy and investigate cross-talk between DNA damage response and immune response. We aim to open new avenues to understanding the oxidative DNA damage response in different chromosomal environments.
Targeting RNA modifying enzymes and R-loops in homologous recombination proficient breast and ovarian cancer
PARP inhibitors (PARPi) are DNA repair targeted drugs that have improved outcomes for tumors which are resistant to hormone therapy and exhibit homologous recombination (HR) deficiency (HRD). However, PARPi are effective only in ~10% of breast or ovarian cancer patients, and patients treated with PARPi inevitably develop drug resistance. Therefore, it is critical to identify HRD-independent vulnerabilities of cancer cells and find new therapeutic targets to complement PARPi therapy. My group has provided fundamental insights into HR in breast cancer and is one of the first to discover an RNA-loop and mRNA dependent DNA Repair (RDDR) pathway, which is upregulated in cancer and maintains cancer cell survival. We set up platforms to validate RDDR activity, keep identifying novel factors of RDDR, develop and validate RDDR inhibitors for cancer therapy. We are also developing RDDR biomarkers to identify tumors harboring increased RDDR activity and predict drug sensitivity. We currently focus on understanding the function and targeting mRNA modifying enzymes of RDDR. RDDR inhibitors should be effective in treating a significant fraction of breast cancer patients, including those who do or do not have HRD and significant fraction of PARPi and hormone therapy-resistant breast cancer patients.
Targeting R-loop-dependent telomere protections upon damage in cancer
Oxidative DNA damage at telomeres is a source of genomic instability, which fuels both aging and tumorigenesis. To bypass senescence, cancer cells have to extend and maintain telomeres during cell division. While the majority of human cancers activate telomerase, a small but significant fraction (~10-15%) of cancers use the alternative lengthening of telomere (ALT) pathway to extend telomeres. We discovered a novel DNA repair pathway contributing to telomere maintenance. This pathway involves TERRA, a non-coding RNA generated at telomeres and R-loops. Our goal is to understand and develop new strategies to exploit the cellular dependency on telomerase, ALT, and R-loop-mediated repair pathways to kill cancer cells harboring high telomeric oxidative damage.
Crosstalk between DDR and immune response upon damage in cancer
DNA sensor cGAS triggers STING-dependent innate immune response and subsequently alters the tumor microenvironment to enhance anti-tumor immunity. The Lan laboratory focuses on 1) understanding how DDR inhibition and/or damage trigger cGAS-STING activation; and 2) how the function of cGAS in the nucleus regulates replication, transcription, and chromatin accessibilities in cancer cells. Our goal is to elucidate the function of cGAS and efficiently target it with the combination with DDR-based therapy in cancer.
Postdoctoral/Lab Technician Positions
Postdoctoral/lab technician positions are available in the Lan Lab. We are studying mechanisms of DNA damage response that are relevant to tumorigenesis, aging, and effective therapeutic approaches for cancer. For Postdoctoral positions, candidates who are interested in DNA damage and cancer with a PhD and/or MD degree, and with experience in biochemical, cell biological, genetic, imaging, bioinformatics, or animal research are encouraged to apply.
Please send a CV with past research experience and the contact information of three references to Li Lan at Llan1@mgh.harvard.edu.
Yang H, Wang Y, Xiang Y, Yadav T, Shi Y, Zou L, Lan L* FMRP Promotes transcription-coupled homologous recombination via Facilitating TET1- mediated m5C RNA modification Demethylation. Proc Natl Acad Sci USA. 2022 Mar 22; 119(12): e2116251119.
Petermann E*, Lan L*, and Zou L*. Sources, resolution and Impact of R-loops and other RNA-DNA hybrids. Nature Reviews Molecular Cell Biology 2022. In press.
Ouyang J, Yadav T, Zhang JM, Yang H, Rheinbay E, Guo H, Haber DA, Lan L, Zou L. RNA transcripts stimulate homologous recombination by forming DR-loops. Nature. 2021 Jun;594(7862):283-288.
Zhu X, Wang X, Yan W, Li H, Lan L. Ubiquitination-mediated degradation of TRDMT1 regulates Homologous Recombination and therapeutic response. NAR Cancer. 2021. 3,1:zcab010.
Chen H, Chen H2, Zhang J, Wang Y, Simoneau A, Yang H, Levine AS, Zou L, Chen Z, and Lan L. cGAS Suppresses Genomic Instability as a Decelerator of Replication Forks. Science Advances, 2020 Oct 14;6(42):eabb8941.
Chen H, Yang H, Zhu X, Yadav T, J, Zou L, Levine AS, Vasudevan S, Lan L. m5C Modification of mRNA Serves a DNA Damage Code to Promote Homologous Recombination. Nature Communications. 2020 June 5th. 11, 2834. Featured article
Tan J, Duan M, Yadav T, Phoon L, Wang X, Zhang JM, Zou L, Lan L. An R-loop-initiated CSB-RAD52-POLD3 pathway suppresses ROS-induced telomeric DNA breaks. Nucleic Acids Res. 2020 Feb 20;48(3):1285-1300.
Tan R, Nakajima S, Wang Q, Sun H, Xue J, Wu J, Hellwig S, Zeng X, Yates N, Smithgall TE, Lei M, Jiang Y, Levine AS, Su B, Lan L. Nek7 protects telomeres from oxidative DNA damage by phosphorylation and stabilization of TRF1. Mol Cell. 2017 Mar 2;65(5):818-831.e5.
The Lan laboratory developed the DNA Damage at RNA Transcribed sites (DART) method to precisely introduce oxidative DNA damage at specific transcribed loci in a dose-dependent manner. This is achieved by site-specific positioning of the photo-excitable and ROS-releasing protein KillerRed (KR).
Li Lan, MD, PhDPrincipal Investigator
- Boya Gao
- Laiyee Phoon
- Jayanth Rao
- Xudong Wang, PhD
- Yao Xiao, MD
- Haibo Yang, PhD
- Haoran Yu
Center for Cancer Research
The scientific engine for discovery for the Mass General Cancer Center.
Support the Center for Cancer Research
When you support the Center for Cancer Research you are enabling discoveries that will lead to effective new weapons in the battle against cancer.
participated in Clinical Trials at the Mass General Cancer Center last year
This helped lead to new knowledge and breakthrough therapies.